Navigation Links
Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
Date:6/19/2013

Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding the potential for NKTR-181 as a potentially new opioid therapy with reduced abuse potential, and the value and potential of our technology and drug candidates in our research and development pipeline.  Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others, (i) NKTR-181 is in the earlier stages of clinical development and could fail at any time due to numerous unpredictable and significant risks related to safety, efficacy and other important findings that can negatively impact clinical development; (ii) although we have conducted various experiments using laboratory and home-based chemistry techniques that have so far been unable to convert NKTR-181 into a rapid-acting, more abusable opioid, it is possible that an alternative chemistry technique or process may be discovered in the future that would enable the conversion of NKTR-181 into a more abusable opi
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
2. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
3. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the Jefferies 2013 Global Healthcare Conference in New York City
4. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
5. Nektar Therapeutics Reports Financial Results for the First Quarter of 2013
6. Nektar to Announce Financial Results for the First Quarter of 2013 on Thursday, May 9, 2013, After Close of U.S.-Based Financial Markets
7. Nektar Therapeutics to Present at the 33rd Annual Cowen and Company Healthcare Conference in Boston
8. Nektar Therapeutics Reports Fourth Quarter and Year-End 2012 Financial Results
9. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
10. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
11. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... July 29, 2014  Drug development for hepatitis ... incidence rates and the intense need for curative ... Change is underway as the market moves away ... effective, easily-tolerated, interferon-free oral therapies. ... Gilead,s mega blockbuster Sovaldi is the first of ...
(Date:7/29/2014)... 29, 2014  Cloud Pharmaceuticals, Inc., a therapeutics ... announced today that it has been awarded a ... Small Business Innovation Research (NSF SBIR) program. The ... Cloud Pharmaceuticals designs new drugs and drug candidates ... innovative cloud computing technology in place of traditional ...
(Date:7/29/2014)... , July 29, 2014  Encision Inc. (OTCQB:ECIA), a ... dangerous stray electrosurgical burns in minimally invasive surgery, today ... ended June 30, 2014. The Company posted ... net loss of $202 thousand, or $(0.02) per share. ... for a net loss of $311 thousand, or $(0.04) ...
Breaking Medicine Technology:A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 3A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 4Cloud Pharmaceuticals Receives Phase I NSF SBIR Grant Valued at $150,000 2Encision Reports First Quarter Fiscal Year 2015 Results 2Encision Reports First Quarter Fiscal Year 2015 Results 3Encision Reports First Quarter Fiscal Year 2015 Results 4
... Pfizer Inc. (NYSE: PFE ) announced ... Capsugel, which may include a divestiture.  Capsugel is ... segment and is the world,s leading provider of ... systems. (Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO) ...
... LAKE, N.J., Oct. 6, 2010 Arena Pharmaceuticals, Inc. ... today upcoming lorcaserin presentations at Obesity 2010, the 28th ... Diego, California. Lorcaserin, which Arena discovered and developed, is ... of weight loss, in patients who are obese (Body ...
Cached Medicine Technology:Pfizer To Review Strategic Alternatives For Capsugel 2Arena and Eisai Announce Upcoming Lorcaserin Presentations at Obesity 2010 2Arena and Eisai Announce Upcoming Lorcaserin Presentations at Obesity 2010 3Arena and Eisai Announce Upcoming Lorcaserin Presentations at Obesity 2010 4
(Date:7/29/2014)... contact lenses may seem like a fun accessory, but ... damage. Decorative contacts should be fitted properly by ... and Drug Administration (FDA). It,s important to get an ... and buy them from a trustworthy seller, the FDA ... health risks associated with decorative contact lenses, the FDA ...
(Date:7/29/2014)... 2014 The Transformer Oil Market in Europe ... with analysis and forecast of revenue. The Transformer Oil market ... in 2013 to $0.5 billion by 2018, at a CAGR ... TOC of the Transformer Oil Market in Europe report, to ... provides a glimpse of the segmentation in the Transformer Oil ...
(Date:7/29/2014)... Pediatric AIDS Foundation (EGPAF) and the American Cancer Society ... essential pain medications for people living with HIV in ... initiative, this new partnership will help improve efforts to ... country. , Swaziland has the highest HIV prevalence ... adults ages 15-49 infected. Many of these individuals also ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Regents Health ... imaging services, has brought health care industry veteran Daryl ... board to help lead the company’s ambitious plans to ... “Regents Health has been moving along at a steady ... kick it up a notch,” says Bob Maier, founder ...
(Date:7/29/2014)... Test instruments after processing to assure ... where it matters most – on the surgical ... premium domestic appliances, introduces ProCare Protein Check, a ... cleaned. The ProCare liquid is applied directly to ... After 3 minutes, users visually determine the presence ...
Breaking Medicine News(10 mins):Health News:It's 'Buyer Beware' for Decorative Contact Lenses, FDA Says 2Health News:Europe Transformer Oil Market is Expected to Reach $0.5 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Transformer Oil Market is Expected to Reach $0.5 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Transformer Oil Market is Expected to Reach $0.5 Billion in 2018 - New Report by MicroMarket Monitor 4Health News:New partnership to improve access to essential pain medications for people living with HIV 2Health News:Sferrella and Demonbruen Join Regents Health Resources 2Health News:ProCare Protein Check Tests Surgical Instruments to Verify Effective Cleaning 2
... significant effect for the more serious, bacterial form of the ... increasingly used to help treat children with bacterial meningitis, but ... treatment may not reduce death rates or the length of ... 2,780 children treated for this potentially lethal infection of tissues ...
... & Vote at,SEIU Hearing, MANHATTAN BEACH, Calif., May ... Employees International Union (SEIU),intensified today as the first in ... of more than 60,000 long-term caregivers who are members,of ... in hospitals, clinics, nursing homes, and home care throughout,California., ...
... U.S. Preventive Medicine(R), (http://www.USPreventiveMedicine.com ) the leader in ... banking team, composed of Credit,Suisse, Deutsche Bank, Merrill ... term capital strategy, mergers and acquisition efforts in ... ), "The selection of some of the ...
... women make it not just a ,man,s disease, anymore ... alcohol dependence has increased substantially among women, particularly white ... finds. , Alcohol use and dependency appeared to ... more lifetime alcohol problems than older Americans, despite having ...
... ADAMS, Mass., May 6 The Lucian Leape Institute ... the,appointment of two new Institute Members: James A. Guest ... Patient Safety,Foundation(R) (NPSF) in May 2007, is a think ... for the field of patient safety. Its,goal is to ...
... ... System, ... and Utilization Review Physicians, Inc. (ABQAURP) is sponsoring,the 3rd Annual Medical ... individuals with chronic or,high-cost conditions. The symposium is scheduled for June ...
Cached Medicine News:Health News:Corticosteroids of Little Use Against Childhood Meningitis 2Health News:Corticosteroids of Little Use Against Childhood Meningitis 3Health News:SEIU Retaliates Against California Caregivers & Democratic Reform Movement 2Health News:U.S. Preventive Medicine Announces Investment Banking Team 2Health News:Alcoholism Gender Gap Is Closing 2Health News:Alcoholism Gender Gap Is Closing 3Health News:The Lucian Leape Institute at the National Patient Safety Foundation Announces the Appointment of Two New Members 2Health News:ABQAURP Hosts Third Annual Medical Management Conference in Orlando 2
Universal vacuum pump (capacity 34 L/min, 8 mbar vacuum abs.)...
... BchiVac V-500 with Vacuum Controller V-800 Efficiently ... turns V-500 on and off as needed to maintain ... Model V-500 is a powerful PTFE membrane vacuum pump ... Ideally suited for use with up to two ...
... V-1000 is a new addition to the powerful ... high performance pump can achieve an ultimate vacuum ... 64 L/min. Applications For use ... Distillation applications from lab size up ...
... is a powerful PTFE membrane vacuum pump designed ... Ideally suited for use with up to ... for instruments including vacuum ovens, concentrators, gel dryers, ... PEEK head resistant to chemicals and heat ...
Medicine Products: